论文部分内容阅读
目的探讨肺耐药相关蛋白(LRP)在膀胱癌组织中的表达及与临床病理参数的关系。方法用半定量逆转录聚合酶链反应(RTPCR)技术,检测66例(Ta期12例,T1期26例,T2期11例,T3期10例,T4期7例;G135例,G219例,G312例)术前未经任何治疗的原发膀胱癌患者癌组织及正常组织中LRP、多药耐药基因1(MDR1)和多药耐药相关蛋白1(MRP1)mRNA表达,并用免疫组化法检测LRP、P53和P63蛋白的表达情况。结果(1)膀胱癌标本中,,LRPmRNA的表达率最高(64%,42/66);(2)LRPmRNA水平,正常膀胱组织(142±036)高于膀胱癌组织(080±033,t=282,P<001);低分级膀胱癌组织(G1为139±042)高于高分级癌组织(G2、G3为072±031,t=414,P<001),浅表膀胱癌组织(136±039)高于浸润癌组织(068±030,t=358,P<005);(3)LRPmRNA表达与MDR1或MRP1表达无关,但与其自身的蛋白表达密切相关(r=089,P<001);(4)LRP蛋白表达与低分级、低分期相关(r=081,P<001;r=078,P<005),但与P53、P63表达无关(P>005)。结论膀胱癌组织中,LRPmRNA与蛋白表达一致,且与肿瘤进展有关,可能是膀胱癌内源性多药耐药的预测指标。
Objective To investigate the expression of lung resistance-associated protein (LRP) in bladder cancer and its relationship with clinicopathological parameters. Methods Sixty-six cases (12 cases of Ta, 26 cases of T1, 11 cases of T2, 10 cases of T3, 7 cases of T4, G135 and G219 cases) were detected by semi-quantitative reverse transcriptase polymerase chain reaction G312). The expressions of LRP, MDR1 and MRP1 mRNA in primary cancerous tissues and normal tissues without any treatment before surgery were detected by immunohistochemistry Method to detect the expression of LRP, P53 and P63 protein. Results (1) The expression of LRP mRNA was the highest in bladder cancer specimens (64%, 42/66). (2) The levels of LRP mRNA in normal bladder tissues (142 ± 036) were higher than those in bladder cancer tissues (080 ± 033, 282, P <001). The positive rate of low grade bladder cancer (G1 = 139 ± 042) was higher than that in high grade cancer (G2, G3 = 072 ± 031, (068 ± 030, t = 358, P <005). (3) LRP mRNA expression was not related with MDR1 or MRP1 expression but closely related to its own protein expression (r = 089, P <001) (4) The expression of LRP protein was correlated with low grade and low staging (r = 081, P <001; r = 078, P <005), but not with the expression of P53 and P63 (P> Conclusion The expression of LRP mRNA in bladder cancer is consistent with the progress of the tumor, which may be a predictor of endogenous multidrug resistance in bladder cancer.